Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

Polymedco Joins CancerX to Accelerate Innovation in Cancer Detection and Diagnosis


CORTLANDT MANOR, N.Y., Jan. 30, 2024 /PRNewswire/ -- Polymedco, a leading provider of best-in-class colorectal cancer screening and early detection solutions, is proud to announce its membership in CancerX, a public-private partnership founded as part of the White House's Cancer Moonshot initiative. CancerX is an exclusive network of industry leaders, researchers, and innovators dedicated to advancing the field of cancer research and diagnostics.

Polymedco is proud to announce its membership in CancerX, part of the White House's Cancer Moonshot initiative.

Polymedco's partnership with CancerX reflects both organizations' commitment to fostering innovation, collaboration, and excellence in the pursuit of earlier cancer detection, diagnosis, and treatment.

"Polymedco is honored to join CancerX and work alongside some of the brightest minds in healthcare and innovative companies. This partnership is a significant step toward Polymedco's ultimate goal of saving more lives through broader awareness and expansion of affordable testing to enable early cancer detection." said Doug White CEO at Polymedco.

As a member, Polymedco looks forward to contributing to the goal of saving more lives through early detection, by working to help expand access to screening and support patients and caregivers.

"We're pleased to partner with Polymedco, as part of CancerX, in applying digital innovation to the fight against cancer," said Doug Mirsky, Vice President, Digital Medicine Society. "Through this powerful public-private partnership with our government partners and CancerX members, like Polymedco, we are uniquely suited to address challenges that are impossible for other efforts to impact and deliver demonstrable improvements to people living with and surviving cancer."

This partnership marks a significant milestone in Polymedco's commitment to making early detection more effective, accessible, and affordable. By collaborating with other influential members of CancerX, Polymedco will actively work to drive progress in the development of advanced diagnostic tools and methodologies. Together, we will unleash the power of innovation to fight cancer.

About Polymedco:
Polymedco partners with healthcare systems, payors, providers, and reference labs to develop best-in-class screening and early detection programs that can help identify life-threatening diseases earlier. Polymedco is proud to offer a portfolio of products with exceptional performance, robust clinical evidence, and user-friendly design.

About CancerX:
CancerX is a public-private partnership founded to boost innovation in the fight against cancer. Co-hosted by the Moffitt Cancer Center and Digital Medicine Society (DiMe), alongside the Office for the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH), it convenes the many diverse stakeholders needed to unleash the power of innovation to reduce the burden of cancer for everyone. 

For more ways to partner with Polymedco, please contact Anthony Bercaw.
Email: abercaw@polymedco.com

SOURCE Polymedco, LLC


These press releases may also interest you

30 jun 2024
SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug...

30 jun 2024
"AI in healthcare is extremely challenging. For companies, it requires not only solving scientific problems but also understanding AI technology and respecting the complexity of the healthcare industry." At the 15th Annual Meeting of the New...

30 jun 2024
"AI in healthcare is extremely challenging. For companies, it requires not only solving scientific problems but also understanding AI technology and respecting the complexity of the healthcare industry." At the 15th Annual Meeting of the New...

30 jun 2024
On June 27, 2024, Yidu Tech Inc. (the ''Company'' or ''Yidu Tech'') (2158.HK), a leader in China's AI medical industry, announced its results for the 2024 fiscal year. During the reporting period, the Company recorded revenue of RMB 807.1 million....

30 jun 2024
Yidu Tech Inc. ("Yidu Tech" or the "Company", together with its subsidiaries and consolidated affiliated entities, the "Group", HKEX: 2158) announced its annual results for the fiscal year ended 31 March 2024 ("FY2024" or the "Reporting Period"). The...

30 jun 2024
CBC Group ("CBC"), Asia's largest healthcare-dedicated asset management firm headquartered in Singapore, announced that its controlled portfolio company, Hasten Biopharmaceutical ("Hasten"), an innovation-driven biopharmaceutical company, has...



News published on and distributed by: